Katherine M Buettner et al.
Dalton transactions (Cambridge, England : 2003), 40(37), 9580-9588 (2011-08-19)
Since the discovery of the anticancer activity of titanocene dichloride (TDC), many derivatives have been developed and evaluated. MKT4, a soluble, water-stable formulation of TDC, was used for both Phase I and Phase II human clinical trials. This formulation is